Last reviewed · How we verify
Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.
Details
| Lead sponsor | Asociación para Evitar la Ceguera en México |
|---|---|
| Phase | Phase 3 |
| Status | WITHDRAWN |
| Start date | 2006-12 |
| Completion | 2006-12 |
Conditions
- Vogt Koyanagi Harada Disease
- Serpiginous Choroiditis
- Multifocal Choroiditis
Interventions
- Bevacizumab
- Intravitreal Injection of Bevacizumab
Primary outcomes
- Best corrected visual acuity
- Retinal thickness by OCT
- Leakage in Fluorescein angiogram
Countries
Mexico